<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities include GDM-specific therapies, safer insulin and oral options, digital glucose monitoring, personalized nutrition, postpartum diabetes prevention, and improved access. A limited drug pipeline and unmet maternal-fetal needs create room for innovation.Dublin, Aug. 14, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6219875/gestational-diabetes-market-insight?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=p785b5&amp;utm_campaign=2325558+-+Gestational+Diabetes+Market+Report+Highlights+Epidemiology%2c+Treatment+Trends+and+Growth+Opportunities+Through+2034&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Gestational Diabetes - Market Insight, Epidemiology, and Market Forecast - 2034">"Gestational Diabetes - Market Insight, Epidemiology, and Market Forecast - 2034"</a> has been added to ResearchAndMarkets.com's offering. The "Gestational Diabetes - Market Insight, Epidemiology, and Market Forecast - 2034" report provides a comprehensive assessment of the gestational diabetes market, including historical and forecasted epidemiology, current treatment practices, emerging therapies, market access, unmet needs and commercial opportunities. The analysis covers the United States, EU4 countries comprising Germany, France, Italy and Spain, the United Kingdom, and Japan from 2020 to 2034. Key Highlights <ul><li>Gestational diabetes management begins with dietary intervention, physical activity and regular glucose monitoring. The American Diabetes Association recommends individualized nutritional counseling provided by a registered dietitian and aligned with the patient's body mass index and pregnancy requirements.</li><li>Women diagnosed with gestational diabetes face an estimated 35% to 60% risk of developing diabetes mellitus within 10 to 20 years after pregnancy.</li><li>Insulin remains the preferred first-line pharmacologic treatment when glycemic targets cannot be achieved through lifestyle interventions.</li><li>Metformin and glyburide are used in clinical practice despite lacking specific FDA approval for gestational diabetes and presenting concerns related to placental transfer and fetal exposure.</li><li>The gestational diabetes therapeutic pipeline remains limited, creating substantial opportunities for targeted drug development, digital monitoring technologies and individualized care models.</li></ul> Gestational Diabetes Diagnosis and Treatment Landscape Professional organizations recommend gestational diabetes screening between 24 and 28 weeks of pregnancy. The one-step approach uses a fasting two-hour 75-g oral glucose tolerance test and is supported by the International Association of Diabetes and Pregnancy Study Groups and the American Diabetes Association. The two-step approach, preferred by the American College of Obstetricians and Gynecologists, begins with a nonfasting one-hour 50-g glucose challenge test, followed by a three-hour 100-g oral glucose tolerance test when the initial result is abnormal. Initial management focuses on medical nutrition therapy, moderate-intensity physical activity and glucose monitoring. When these measures do not provide adequate glycemic control, insulin is generally recommended because of its established efficacy and pregnancy safety profile. Treatment regimens may combine basal insulin for fasting hyperglycemia with short-acting insulin for postprandial elevations. Dosing is adjusted according to maternal weight, gestational age and glucose trends. Although metformin may offer convenient administration and favorable maternal weight outcomes, it crosses the placenta, and its long-term effects on offspring continue to be studied. Glyburide has been associated with increased risks of neonatal hypoglycemia and macrosomia compared with insulin. These considerations reinforce insulin's position as the standard pharmacologic option when lifestyle management is insufficient. Gestational Diabetes Epidemiology The report evaluates total prevalent, type-specific, age-specific and treated cases of gestational diabetes across the seven major markets. Gestational diabetes affects approximately 2% to 10% of pregnancies in the United States. Prevalence rises with maternal age; in 2021, the reported rate among mothers aged 40 years and older reached 15.6%, compared with 2.7% among mothers younger than 20 years. In Europe, gestational diabetes prevalence was estimated at 5.4% in 2023. The increasing prevalence of gestational diabetes, together with its long-term metabolic consequences, is expected to sustain demand for earlier diagnosis, improved glucose monitoring and effective maternal-fetal treatment strategies. Emerging Therapies and Pipeline Activity AFREZZA, MannKind's inhaled Technosphere insulin, is among the notable candidates under investigation for gestational diabetes. The therapy is being evaluated in a Phase II/III program, and the company reported the launch of an investigator-initiated gestational diabetes trial in the second quarter of 2025. The broader gestational diabetes pipeline remains scarce, with limited innovation beyond the repurposing of established diabetes therapies. Recent advances have primarily involved digital glucose monitoring, individualized nutrition counseling and improved care delivery rather than newly approved gestational diabetes-specific medicines. This limited pipeline underscores the need for therapies that demonstrate benefits across maternal glycemic control, pregnancy outcomes and long-term offspring health. Market Outlook and Competitive Intelligence The gestational diabetes market report analyzes therapy uptake, market share, competitive positioning and forecasted market size through 2034. It also reviews clinical development programs, mechanisms of action, trial outcomes, collaborations, licensing agreements, mergers and acquisitions, patent activity and regulatory developments. Insights from more than 30 key opinion leaders were gathered, with over 10 interviews conducted across the seven major markets. Participating and contacted institutions included Washington University School of Medicine, University Medical Center Hamburg-Eppendorf and other leading academic centers. These perspectives support validation of epidemiology estimates, treatment patterns, unmet needs and future market trends. Report Coverage <ul><li>Historical and forecasted gestational diabetes epidemiology from 2020 to 2034</li><li>Market size, therapy share and drug uptake across the seven major markets</li><li>Current treatment algorithms and prescribing trends</li><li>Emerging therapy profiles and clinical pipeline analysis</li><li>SWOT and conjoint analysis of market opportunities</li><li>Country-specific market access, reimbursement and affordability insights</li><li>Competitive intelligence covering collaborations, licensing, acquisitions and patents</li></ul> Business Value The report supports pharmaceutical companies, investors, healthcare organizations and market-access teams in identifying growth opportunities within the gestational diabetes market. It provides actionable intelligence for portfolio planning, product positioning, clinical development, sales strategy and geographic expansion across the United States, Europe and Japan. By combining epidemiology forecasts, treatment analysis, pipeline assessment and expert insights, the report enables stakeholders to evaluate future competition, identify high-potential markets and develop strategies addressing the significant unmet needs of patients with gestational diabetes. Key Topics Covered: 1. Key Insights 2. Report Introduction 3. Executive Summary of Gestational Diabetes 4. Key Events 5. Gestational Diabetes Epidemiology and Market Forecast Methodology 6. Gestational Diabetes Market Overview at a Glance 6.1. Market Share (%) Distribution of Gestational Diabetes by Therapies in 2024 6.2. Market Share (%) Distribution of Gestational Diabetes by Therapies in 2034 7. Disease Background and Overview: Gestational Diabetes 7.1. Introduction 7.2. Signs and Symptoms 7.3. Causes 7.4. Diagnosis 8. Treatment and Management 8.1. Treatment Guidelines and Recommendations 9. Epidemiology and Patient Population of Gestational Diabetes in the 7MM 9.1. Key Findings 9.2. Assumptions and Rationale 9.3. Total Prevalent Cases of Gestational Diabetes in the 7MM 9.4. The United States 9.4.1. Total Prevalent Cases of Gestational Diabetes in the United States [2020-2034] 9.4.2. Type-specific Cases of Gestational Diabetes in the United States [2020-2034] 9.4.3. Age-specific Cases of Gestational Diabetes in the United States [2020-2034] 9.4.4. Total Treated Cases of Gestational Diabetes in the United States [2020-2034] 9.5. EU4 and the UK 9.5.1. Total Prevalent Cases of Gestational Diabetes in EU4 and the UK [2020-2034] 9.5.2. Type-specific Cases of Gestational Diabetes in EU4 and the UK [2020-2034] 9.5.3. Age-specific Cases of Gestational Diabetes in EU4 and the UK [2020-2034] 9.5.4. Total Treated Cases of Gestational Diabetes in EU4 and the UK [2020-2034] 9.6. Japan 9.6.1. Total Prevalent Cases of Gestational Diabetes in Japan [2020-2034] 9.6.2. Type-specific Cases of Gestational Diabetes in Japan [2020-2034] 9.6.3. Age-specific Cases of Gestational Diabetes in Japan [2020-2034] 9.6.4. Total Treated Cases of Gestational Diabetes in Japan [2020-2034] 10. Patient Journey 11. Emerging Drugs 11.1. Key Competitors 11.2. AFREZZA (Inhaled Technosphere Insulin): Mannkind 11.2.1. Product Description 11.2.2. Other Developmental Activity 11.2.3. Clinical Developmental Activities 11.2.4. Safety and efficacy 11.2.5. Analyst Views 12. Gestational Diabetes: Seven Major Market Analysis 12.1. Key Findings 12.2. Key Market Forecast Assumptions 12.3. Market Outlook 12.4. Total Market Size of Gestational Diabetes in the 7MM 12.5. United States Market Size 12.5.1. Total Market Size of Gestational Diabetes in the United States 12.5.2. Market Size of Gestational Diabetes by Therapies in the United States 12.6. EU4 and the UK Market Size 12.6.1. Total Market Size of Gestational Diabetes in EU4 and the UK 12.6.2. Market size of Gestational Diabetes by Therapies in EU4 and the UK 12.7. Japan Market Size 12.7.1. Total Market Size of Gestational Diabetes in Japan 12.7.2. Market Size of Gestational Diabetes by Therapies in Japan 13. Unmet Needs 14. SWOT Analysis 15. KOL Views 16. Market Access and Reimbursement 17. Appendix 17.1. Bibliography 17.2. Report Methodology 18. Publisher Capabilities 19. Disclaimer 20. About the Publisher List of Tables Table 1: 7MM Gestational Diabetes Epidemiology (2020-2034) Table 2: 7MM Gestational Diabetes Diagnosed and Treatable Cases (2020-2034) Table 3: Gestational Diabetes Epidemiology in the United States (2020-2034) Table 4: Gestational Diabetes Diagnosed and Treatable Cases in the United States (2020-2034) Table 5: Gestational Diabetes Epidemiology in Germany (2020-2034) Table 6: Gestational Diabetes Diagnosed and Treatable Cases in Germany (2020-2034) Table 7: Gestational Diabetes Epidemiology in France (2020-2034) Table 8: Gestational Diabetes Diagnosed and Treatable Cases in France (2020-2034) Table 9: Gestational Diabetes Epidemiology in Italy (2020-2034) Table 10: Gestational Diabetes Diagnosed and Treatable Cases in Italy (2020-2034) Table 11: Gestational Diabetes Epidemiology in Spain (2020-2034) Table 12: Gestational Diabetes Diagnosed and Treatable Cases in Spain (2020-2034) Table 13: Gestational Diabetes Epidemiology in the UK (2020-2034) Table 14: Gestational Diabetes Diagnosed and Treatable Cases in the UK (2020-2034) Table 15: Gestational Diabetes Epidemiology in Japan (2020-2034) Table 16: Gestational Diabetes Diagnosed and Treatable Cases in Japan (2020-2034) Table 17: Drug Name, Clinical Trials by Recruitment status Table 18: Drug Name, Clinical Trials by Zone Table 19: Total Seven Major Market Size in USD, Million (2020-2034) Table 20: Region-wise Market Size in USD, Million (2020-2034) Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034) Table 22: United States Market Size in USD, Million (2020-2034) Table 23: United States Market Size by Therapy in USD, Million (2020-2034) Table 24: Germany Market Size in USD, Million (2020-2034) Table 25: Germany Market Size by Therapy in USD, Million (2020-2034) Table 26: France Market Size in USD, Million (2020-2034) Table 27: France Market Size by Therapy in USD, Million (2020-2034) Table 28: Italy Market Size in USD, Million (2020-2034) Table 29: Italy Market Size by Therapy in USD, Million (2020-2034) Table 30: Spain Market Size in USD, Million (2020-2034) Table 31: Spain Market Size by Therapy in USD, Million (2020-2034) Table 32: United Kingdom Market Size in USD, Million (2020-2034) Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034) Table 34: Japan Market Size in USD, Million (2020-2034) Table 35: Japan Market Size by Therapy in USD, Million (2020-2034) List of Figures Figure 1: 7MM Gestational Diabetes Epidemiology (2020-2034) Figure 2: 7MM Gestational Diabetes Diagnosed and Treatable Cases (2020-2034) Figure 3: Gestational Diabetes Epidemiology in the United States (2020-2034) Figure 4: Gestational Diabetes Diagnosed and Treatable Cases in the United States (2020-2034) Figure 5: Gestational Diabetes Epidemiology in Germany (2020-2034) Figure 6: Gestational Diabetes Diagnosed and Treatable Cases in Germany (2020-2034) Figure 7: Gestational Diabetes Epidemiology in France (2020-2034) Figure 8: Gestational Diabetes Diagnosed and Treatable Cases in France (2020-2034) Figure 9: Gestational Diabetes Epidemiology in Italy (2020-2034) Figure 10: Gestational Diabetes Diagnosed and Treatable Cases in Italy (2020-2034) Figure 11: Gestational Diabetes Epidemiology in Spain (2020-2034) Figure 12: Gestational Diabetes Diagnosed and Treatable Cases in Spain (2020-2034) Figure 13: Gestational Diabetes Epidemiology in the UK (2020-2034) Figure 14: Gestational Diabetes Diagnosed and Treatable Cases in the UK (2020-2034) Figure 15: Gestational Diabetes Epidemiology in Japan (2020-2034) Figure 16: Gestational Diabetes Diagnosed and Treatable Cases in Japan (2020-2034) Figure 17: Drug Name, Clinical Trials by Recruitment status Figure 18: Drug Name, Clinical Trials by Zone Figure 19: Total Seven Major Market Size in USD, Million (2020-2034) Figure 20: Region-wise Market Size in USD, Million (2020-2034) Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034) Figure 22: United States Market Size in USD, Million (2020-2034) Figure 23: United States Market Size by Therapy in USD, Million (2020-2034) Figure 24: Germany Market Size in USD, Million (2020-2034) Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034) Figure 26: France Market Size in USD, Million (2020-2034) Figure 27: France Market Size by Therapy in USD, Million (2020-2034) Figure 28: Italy Market Size in USD, Million (2020-2034) Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034) Figure 30: Spain Market Size in USD, Million (2020-2034) Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034) Figure 32: United Kingdom Market Size in USD, Million (2020-2034) Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034) Figure 34: Japan Market Size in USD, Million (2020-2034) Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034) A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Mannkind</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6219875/gestational-diabetes-market-insight?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=p785b5&amp;utm_campaign=2325558+-+Gestational+Diabetes+Market+Report+Highlights+Epidemiology%2c+Treatment+Trends+and+Growth+Opportunities+Through+2034&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/jj7iit</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MzMzNzI4ZjgtYmJjNS00MGM5LTg5OTAtNTY5MGIyOTIyZDNiLTEwMjY3MzctMjAyNi0wOC0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Gestational Diabetes Market Report Highlights Epidemiology, Treatment Trends and Growth Opportunities Through 2034

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn